Background
Methods
Cell Lines, transfection, and stable cell line establishment
Microarray array
RTK name | NIH/3T3 | NIH-Met5 day 1 | NIH-Met5 day 4 | NIH-Met5 day 7 |
---|---|---|---|---|
Axl
| -0.43 | 1.48 | -0.71 | -0.34 |
ERBB2 | -0.24 | 1.34 | -1.07 | -0.02 |
ERBB3 | -0.34 | 1.47 | -0.79 | -0.35 |
Met
| 0.02 | 1.18 | -1.26 | 0.06 |
MST1R | -0.35 | 1.45 | -0.84 | -0.26 |
PDGFRα
| -0.40 | 1.48 | -0.70 | -0.38 |
PDGFRβ | -0.20 | 1.13 | -1.25 | 0.32 |
TIE1 | -0.24 | 1.47 | -0.76 | -0.47 |
TIE2 | -0.01 | 1.38 | -0.97 | -0.40 |
Antibodies
Western blot analysis
siRNA transfection
Trans-well migration assay
Clinicopathological characteristics of study cases
Immunohistochemical staining
Statistical analysis
Results
Establishment of stable cell lines harboring inducible c-Met gene
Expression and functional association of c-Met with Axl and PDGFR-α in vitro
Correlation of c-Met expression with Axl and PDGFR-α status in human bladder cancer cells
The involvement of MEK/ERK signaling pathway in the transactivation of Axl and PDGFR-α by c-Met
The effect of cross-talk of c-Met, Axl, and PDGFR-α on cell migration
Clinical implication of c-Met, Axl, and PDGFR-α co-expression patterns in human bladder cancer patients
Expression pattern | Grade | T status* | Multiple | Node (+) | Survival |
---|---|---|---|---|---|
c-Met | 0.561 | 0.904 | 0.727 | 0.321 | 0.009†
|
Axl | 0.409 | 0.105 | 0.795 | 0.300 | 0.789 |
PDGFR-α | 0.344 | 0.470 | 0.718 | 0.049†
| 0.027†
|
c-Met & Axl | 0.140 | 0.070 | 0.277 | 0.061 | 0.031†
|
c-Met & PDGFR-α | 0.184 | 0.686 | 0.957 | 0.802 | 0.011†
|
Axl & PDGFR-α | 0.439 | 0.585 | 0.762 | 0.369 | 0.049†
|
c-Met & Axl & PDGFR-α | 0.595 | 0.377 | 0.346 | 0.281 | 0.008†
|